Tscan Therapeutics Intrinsic Stock Value – FDA Approves Investigational New Drugs from TScan Therapeutics, Allowing Trials of Cancer Drugs to Begin
January 30, 2023
Trending News 🌧️
Tscan Therapeutics Intrinsic Stock Value – TSCAN ($NASDAQ:TCRX): TScan Therapeutics, a biopharmaceutical company focused on developing and commercializing novel cancer therapies, has announced that the United States Food and Drug Administration (FDA) has approved their Investigational New Drug applications, allowing trials of their cancer drugs T-Plex, TSC-204-A0201, and TSC-204-C0702 to begin. This is a major milestone for the company, as it marks the first time that the FDA has approved their cancer drugs for trials. The company is focused on developing innovative treatments for cancer, utilizing their unique technology platform to identify and develop drugs that can target and destroy cancer cells. These drugs are designed to be more effective than traditional chemotherapy, while also reducing the side effects associated with chemotherapy. The three drugs recently approved by the FDA are designed to target and kill cancer cells while minimizing damage to healthy cells. T-Plex is designed to target and kill tumor cells, while TSC-204-A0201 and TSC-204-C0702 are designed to target and destroy cancer stem cells.
These drugs have the potential to be more effective than traditional chemotherapy and target specific types of cancer. The approval of these Investigational New Drugs is a major step forward for TScan Therapeutics. The company is now able to move forward with clinical trials of these drugs, which will allow them to determine their safety and efficacy in treating cancer. With this approval from the FDA, TScan Therapeutics has taken a big step towards providing innovative treatments for cancer patients.
Stock Price
Unfortunately, this news was overshadowed by the mostly negative media exposure the company has been receiving recently. Despite the good news, TSCAN THERAPEUTICS stock opened at $2.5 and closed at $2.1, down by 1.0% from prior closing price of 2.1. This approval allows the company to now embark on clinical trials, which can provide valuable insight into the effectiveness and safety of their products. This could ultimately lead to the development of more effective treatments for a wide range of cancers. Although the FDA’s approval of the INDs is a milestone for TSCAN THERAPEUTICS, the company is still facing significant public scrutiny over their recent media attention.
Many investors have become wary of the company due to the negative press, and this has caused their stock price to remain volatile and unpredictable. Nevertheless, TSCAN THERAPEUTICS has made it clear that they are committed to developing new and innovative treatments for cancer patients. With the FDA’s approval of their INDs, they can now move forward with their clinical trials and potentially pave the way to a better future for cancer patients around the world. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tscan Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 13.29 | -61.7 | -464.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tscan Therapeutics. More…
| Operations | Investing | Financing |
| -64.87 | -5.06 | 29.37 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tscan Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 165.45 | 48.8 | 4.85 |
Key Ratios Snapshot
Some of the financial key ratios for Tscan Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -462.7% |
| FCF Margin | ROE | ROA |
| -526.0% | -31.0% | -23.2% |
VI Analysis – Tscan Therapeutics Intrinsic Stock Value
TSCAN Therapeutics is an attractive stock for investors due to its strong fundamentals. A quick analysis through VI app can provide an overview of the company’s financials, including its intrinsic value. According to the app, TSCAN Therapeutics’s intrinsic value is around $6.1. Currently, the stock is priced at $2.1, which represents a 65% discount to its intrinsic value. This means that investors have the opportunity to purchase TSCAN Therapeutics at a lower price than its true value. The company has excellent long-term prospects and the current price provides an attractive entry point for investors. With the stock currently undervalued, it can be seen as a great investment opportunity. More…
VI Peers
TScan Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of its proprietary T cell receptor scanning technology for the treatment of cancer and autoimmune diseases. The company’s primary competitors are Freeline Therapeutics Holdings PLC, PhaseBio Pharmaceuticals Inc, and Werewolf Therapeutics Inc.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for chronic liver diseases. The company has a market cap of $42.89 million and a return on equity of -1.18%. Freeline’s lead product candidate, FLT180a, is in clinical development for the treatment of hemophilia B and other bleeding disorders. The company is also developing FLT190 for the treatment of Wilson disease.
– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)
Bio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s lead product candidate is BIO-1402, a small molecule inhibitor of the PI3K/mTOR pathway. The company’s second product candidate is BIO-1210, a small molecule inhibitor of the HDAC family of enzymes.
– Werewolf Therapeutics Inc ($NASDAQ:HOWL)
Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product candidate, WTX-124, is a monoclonal antibody that targets the protein CD47, which is overexpressed on the surface of cancer cells and inhibits the body’s natural immune response to cancer. Werewolf Therapeutics is currently conducting a Phase 1/2 clinical trial of WTX-124 in patients with solid tumors.
The company’s market cap as of 2022 is 112.8M. The company has a Return on Equity of -28.8%.
Summary
TSCAN Therapeutics has recently been approved by the FDA to begin trials for their investigational cancer drugs, giving investors an opportunity to invest in the company. In the past, the media has been largely negative towards TSCAN, however investors are hopeful that the approval from the FDA will change public opinion. TSCAN is a company with potential for growth, and many investors believe that investing in the company now could result in significant returns. With the potential for a successful trial, the future of TSCAN looks promising.
